



99TH GENERAL ASSEMBLY

State of Illinois

2015 and 2016

HB3588

by Rep. Michael J. Zalewski

SYNOPSIS AS INTRODUCED:

See Index

Creates the Synthetic Drug Identification Pilot Program Act. Provides that at least once every 90 days, and in consultation with the Division of Forensic Services of the Department of State Police, the Department of Human Services shall submit a report to the Governor, Attorney General, and General Assembly outlining whether the Division of Forensic Services of the Department of State Police has identified any new chemical formulas that are used to make synthetic cannabinoids or cathinones (synthetic drugs) that are not currently illegal under State law. Provides that if the Department of Human Services' report to the Governor, Attorney General, and General Assembly confirms the Department of Human Services has identified new chemical formulas that are used to make synthetic drugs, the Department Human Services shall as soon as practicable propose an emergency rule to add any new chemical formulas to the current list of chemical formulas that are listed in the Illinois Controlled Substances Act as Schedule I controlled substances, and adopt the proposed rule as quickly as allowed for under the Illinois Administrative Procedure Act. Provides that if the Department of Human Services adopts the emergency rule, the new rule shall be recognized as law under the Illinois Controlled Substances Act. Provides that the Department of State Police, by rule, shall create a pilot program that uses technologies and protocols to instantly identify synthetic cannabinoids and cathinones (synthetic drugs), as well as other designer drugs. Provides that the pilot program shall focus on using technology capable of presumptive identification of illicit drugs in the field. Repeals the Act on July 30, 2018. Amends the Illinois Controlled Substances Act to make conforming changes. Effective immediately.

LRB099 07636 RLC 27767 b

FISCAL NOTE ACT
MAY APPLY

A BILL FOR

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 1. Short title. This Act may be cited as the
5 Synthetic Drug Identification Pilot Program Act.

6 Section 5. Legislative intent. The General Assembly
7 recognizes the recent growth of synthetic drugs, such as
8 Spice/K2 and Bath Salts, and the dangers caused by these
9 substances. The concern is exemplified by a Substance Abuse and
10 Mental Health Services Administration report which summarizes
11 the frequency and trends of abuse for these substances. The
12 General Assembly further recognizes that better methods and
13 strategies that appropriately respond to new synthetic drugs as
14 soon as they are made known to the State is of particular
15 importance. The General Assembly further recognizes that law
16 enforcement is in need of presumptive testing tools capable of
17 quickly identifying substances as illegal synthetic drugs
18 defined under State law. It is the intent of this legislation
19 to create a process by which synthetic drugs can be quickly
20 outlawed under State law and instantly identified by police in
21 the field.

22 Section 10. Department of Human Services; emergency rule.

1 (a) At least once every 90 days, and in consultation with
2 the Division of Forensic Services of the Department of State
3 Police, the Department of Human Services shall submit a report
4 to the Governor, Attorney General, and General Assembly
5 outlining whether the Division of Forensic Services of the
6 Department of State Police has identified any new chemical
7 formulas that are used to make synthetic cannabinoids or
8 cathinones (synthetic drugs) that are not currently illegal
9 under State law. To identify new chemical formulas, the
10 Department of Human Services shall, among other activities,
11 routinely communicate with the Division of Forensic Services of
12 the Department of State Police, the United States Drug
13 Enforcement Administration, the United States Office of
14 National Drug Control Policy, and the Scientific Working Group
15 for the Analysis of Seized Drugs (SWDRUG), and agencies of
16 other states involved in drug schedule classifications.

17 (b) If the Department of Human Services' report to the
18 Governor, Attorney General, and General Assembly confirms the
19 Department of Human Services has identified new chemical
20 formulas that are used to make synthetic drugs, the Department
21 of Human Services shall as soon as practicable propose an
22 emergency rule to add any new chemical formulas to the current
23 list of chemical formulas that are listed in Section 204 of the
24 Illinois Controlled Substances Act as Schedule I controlled
25 substances, and adopt the proposed rule as quickly as allowed
26 for under the Illinois Administrative Procedure Act. If the

1 Department of Human Services adopts the emergency rule under
2 this subsection, the rule shall have the force of law under
3 Section 204 of the Illinois Controlled Substances Act.

4 (c) Any emergency rule adopted under this Section shall be
5 inoperative in 12 months from the date that the emergency rule
6 becomes effective, or when the General Assembly takes action to
7 ratify, change, or reject the emergency rule enacted by the
8 Department of Human Services.

9 (d) Nothing in this Section shall interfere with the
10 exemptions provided for under State law to any person or entity
11 that possesses a chemical formula defined as a scheduled drug
12 for a lawful purpose.

13 Section 15. Law enforcement field testing to instantly
14 identify synthetic drugs.

15 (a) The Department of State Police, by rule, shall create a
16 pilot program that uses technologies and protocols to instantly
17 identify synthetic cannabinoids and cathinones (synthetic
18 drugs), as well as other designer drugs. The pilot program
19 shall focus on using technology capable of presumptive
20 identification of illicit drugs in the field.

21 (b) A minimum of 5 separate State Police districts in the
22 State shall be equipped to operate the pilot program. The
23 Department of State Police may choose to have one or more of
24 the pilot sites located within a municipal or county police
25 department.

1 (c) Before July 30, 2018, the Department of State Police
2 shall submit a report to the General Assembly outlining the
3 findings of the pilot program, and make any recommendation on
4 whether the technologies and protocols selected for the pilot
5 program can be used to help prevent the growth of synthetic
6 drugs and other illicit drugs throughout the State.
7 Specifically, the evaluation shall include, but is not limited
8 to the following:

9 (1) Review of technical capabilities and accuracy
10 rates of technologies and protocols selected for the pilot
11 program.

12 (2) Describe the impact to State and local crime
13 laboratory backlogs if the technologies and protocols
14 selected could eliminate the need to send synthetic drugs,
15 or other illicit drugs to the crime laboratory for
16 presumptive testing, including the potential cost savings
17 to State and local government.

18 (3) Describe the status of court acceptance of the
19 technologies and protocols selected for the pilot program
20 for the presumptive identification of synthetic drugs and
21 other illicit drugs.

22 Section 20. Repeal. This Act is repealed on July 30, 2018.

23 Section 105. The Illinois Controlled Substances Act is
24 amended by changing Section 204 as follows:

1 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

2 Sec. 204. (a) The controlled substances listed in this
3 Section are included in Schedule I.

4 (b) Unless specifically excepted or unless listed in
5 another schedule, any of the following opiates, including their
6 isomers, esters, ethers, salts, and salts of isomers, esters,
7 and ethers, whenever the existence of such isomers, esters,
8 ethers and salts is possible within the specific chemical
9 designation:

10 (1) Acetylmethadol;

11 (1.1) Acetyl-alpha-methylfentanyl

12 (N-[1-(1-methyl-2-phenethyl)-
13 4-piperidinyl] -N-phenylacetamide);

14 (2) Allylprodine;

15 (3) Alphacetylmethadol, except
16 levo-alphacetylmethadol (also known as levo-alpha-
17 acetylmethadol, levomethadyl acetate, or LAAM);

18 (4) Alphameprodine;

19 (5) Alphamethadol;

20 (6) Alpha-methylfentanyl

21 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
22 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
23 propanilido) piperidine;

24 (6.1) Alpha-methylthiofentanyl

25 (N-[1-methyl-2-(2-thienyl)ethyl-

- 1 4-piperidinyl] -N-phenylpropanamide);
- 2 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
- 3 (7.1) PEPAP
- 4 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 5 (8) Benzethidine;
- 6 (9) Betacetylmethadol;
- 7 (9.1) Beta-hydroxyfentanyl
- 8 (N-[1-(2-hydroxy-2-phenethyl)-
- 9 4-piperidinyl] -N-phenylpropanamide);
- 10 (10) Betameprodine;
- 11 (11) Betamethadol;
- 12 (12) Betaprodine;
- 13 (13) Clonitazene;
- 14 (14) Dextromoramide;
- 15 (15) Diampromide;
- 16 (16) Diethylthiambutene;
- 17 (17) Difenoxin;
- 18 (18) Dimenoxadol;
- 19 (19) Dimepheptanol;
- 20 (20) Dimethylthiambutene;
- 21 (21) Dioxaphetylbutyrate;
- 22 (22) Dipipanone;
- 23 (23) Ethylmethylthiambutene;
- 24 (24) Etonitazene;
- 25 (25) Etoxeridine;
- 26 (26) Furethidine;

- 1 (27) Hydroxypethidine;
- 2 (28) Ketobemidone;
- 3 (29) Levomoramide;
- 4 (30) Levophenacylmorphane;
- 5 (31) 3-Methylfentanyl
6 (N-[3-methyl-1-(2-phenylethyl) -
7 4-piperidyl] -N-phenylpropanamide);
- 8 (31.1) 3-Methylthiofentanyl
9 (N-[(3-methyl-1-(2-thienyl)ethyl-
10 4-piperidinyl] -N-phenylpropanamide);
- 11 (32) Morpheridine;
- 12 (33) Noracymethadol;
- 13 (34) Norlevorphanol;
- 14 (35) Normethadone;
- 15 (36) Norpipanone;
- 16 (36.1) Para-fluorofentanyl
17 (N-(4-fluorophenyl)-N-[1-(2-phenethyl) -
18 4-piperidinyl] propanamide);
- 19 (37) Phenadoxone;
- 20 (38) Phenampromide;
- 21 (39) Phenomorphan;
- 22 (40) Phenoperidine;
- 23 (41) Piritramide;
- 24 (42) Proheptazine;
- 25 (43) Properidine;
- 26 (44) Propiram;

- 1 (45) Racemoramide;
2 (45.1) Thiofentanyl
3 (N-phenyl-N-[1-(2-thienyl)ethyl-
4 4-piperidinyl] -propanamide);
5 (46) Tilidine;
6 (47) Trimeperidine;
7 (48) Beta-hydroxy-3-methylfentanyl (other name:
8 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl] -
9 N-phenylpropanamide).

10 (c) Unless specifically excepted or unless listed in
11 another schedule, any of the following opium derivatives, its
12 salts, isomers and salts of isomers, whenever the existence of
13 such salts, isomers and salts of isomers is possible within the
14 specific chemical designation:

- 15 (1) Acetorphine;
16 (2) Acetyldihydrocodeine;
17 (3) Benzylmorphine;
18 (4) Codeine methylbromide;
19 (5) Codeine-N-Oxide;
20 (6) Cyprenorphine;
21 (7) Desomorphine;
22 (8) Diacetyldihydromorphine (Dihydroheroin);
23 (9) Dihydromorphine;
24 (10) Drotebanol;
25 (11) Etorphine (except hydrochloride salt);
26 (12) Heroin;

- 1 (13) Hydromorphenol;
- 2 (14) Methyldesorphine;
- 3 (15) Methyldihydromorphine;
- 4 (16) Morphine methylbromide;
- 5 (17) Morphine methylsulfonate;
- 6 (18) Morphine-N-Oxide;
- 7 (19) Myrophine;
- 8 (20) Nicocodeine;
- 9 (21) Nicomorphine;
- 10 (22) Normorphine;
- 11 (23) Pholcodine;
- 12 (24) Thebacon.

13 (d) Unless specifically excepted or unless listed in
14 another schedule, any material, compound, mixture, or
15 preparation which contains any quantity of the following
16 hallucinogenic substances, or which contains any of its salts,
17 isomers and salts of isomers, whenever the existence of such
18 salts, isomers, and salts of isomers is possible within the
19 specific chemical designation (for the purposes of this
20 paragraph only, the term "isomer" includes the optical,
21 position and geometric isomers):

- 22 (1) 3,4-methylenedioxyamphetamine
23 (alpha-methyl,3,4-methylenedioxyphenethylamine,
24 methylenedioxyamphetamine, MDA);
25 (1.1) Alpha-ethyltryptamine
26 (some trade or other names: etryptamine;

1 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
2 3-(2-aminobutyl)indole; a-ET; and AET);
3 (2) 3,4-methylenedioxymethamphetamine (MDMA);
4 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
5 (also known as: N-ethyl-alpha-methyl-
6 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
7 and MDEA);
8 (2.2) N-Benzylpiperazine (BZP);
9 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
10 (4) 3,4,5-trimethoxyamphetamine (TMA);
11 (5) (Blank);
12 (6) Diethyltryptamine (DET);
13 (7) Dimethyltryptamine (DMT);
14 (7.1) 5-Methoxy-diallyltryptamine;
15 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
16 (9) Ibogaine (some trade and other names:
17 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
18 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
19 indole; Tabernanthe iboga);
20 (10) Lysergic acid diethylamide;
21 (10.1) Salvinorin A;
22 (10.5) Salvia divinorum (meaning all parts of the plant
23 presently classified botanically as Salvia divinorum,
24 whether growing or not, the seeds thereof, any extract from
25 any part of that plant, and every compound, manufacture,
26 salts, isomers, and salts of isomers whenever the existence

1 of such salts, isomers, and salts of isomers is possible
2 within the specific chemical designation, derivative,
3 mixture, or preparation of that plant, its seeds or
4 extracts);

5 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

6 (12) Peyote (meaning all parts of the plant presently
7 classified botanically as *Lophophora williamsii* Lemaire,
8 whether growing or not, the seeds thereof, any extract from
9 any part of that plant, and every compound, manufacture,
10 salts, derivative, mixture, or preparation of that plant,
11 its seeds or extracts);

12 (13) N-ethyl-3-piperidyl benzilate (JB 318);

13 (14) N-methyl-3-piperidyl benzilate;

14 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
15 (also known as N-hydroxy-alpha-methyl-
16 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

17 (15) Parahexyl; some trade or other names:
18 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
19 dibenzo (b,d) pyran; Synhexyl;

20 (16) Psilocybin;

21 (17) Psilocyn;

22 (18) Alpha-methyltryptamine (AMT);

23 (19) 2,5-dimethoxyamphetamine
24 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

25 (20) 4-bromo-2,5-dimethoxyamphetamine
26 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;

1 4-bromo-2,5-DMA);

2 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

3 Some trade or other names: 2-(4-bromo-

4 2,5-dimethoxyphenyl)-1-aminoethane;

5 alpha-desmethyl DOB, 2CB, Nexus;

6 (21) 4-methoxyamphetamine

7 (4-methoxy-alpha-methylphenethylamine;

8 paramethoxyamphetamine; PMA);

9 (22) (Blank);

10 (23) Ethylamine analog of phencyclidine.

11 Some trade or other names:

12 N-ethyl-1-phenylcyclohexylamine,

13 (1-phenylcyclohexyl) ethylamine,

14 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;

15 (24) Pyrrolidine analog of phencyclidine. Some trade

16 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,

17 PHP;

18 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;

19 (26) 2,5-dimethoxy-4-ethylamphetamine

20 (another name: DOET);

21 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

22 (another name: TCPy);

23 (28) (Blank);

24 (29) Thiophene analog of phencyclidine (some trade

25 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;

26 2-thienyl analog of phencyclidine; TPCP; TCP);

1 (30) Bufotenine (some trade or other names:

2 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

3 3-(2-dimethylaminoethyl)-5-indolol;

4 5-hydroxy-N,N-dimethyltryptamine;

5 N,N-dimethylserotonin; mappine);

6 (31) 1-Pentyl-3-(1-naphthoyl)indole

7 Some trade or other names: JWH-018;

8 (32) 1-Butyl-3-(1-naphthoyl)indole

9 Some trade or other names: JWH-073;

10 (33) 1-[(5-fluoropentyl)-1H-indol-3-yl] -

11 (2-iodophenyl)methanone

12 Some trade or other names: AM-694;

13 (34) 2-[(1R,3S)-3-hydroxycyclohexyl] -5-

14 (2-methyloctan-2-yl)phenol

15 Some trade or other names: CP 47,497

16 and its C6, C8 and C9 homologs;

17 (34.5) 2-[(1R,3S)-3-hydroxycyclohexyl] -5-

18 (2-methyloctan-2-yl)phenol), where side chain n=5;

19 and homologues where side chain n=4, 6, or 7; Some

20 trade or other names: CP 47,497;

21 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-

22 (2-methyloctan-2-yl)-6a,7,

23 10,10a-tetrahydrobenzo[c] chromen-1-ol

24 Some trade or other names: HU-210;

25 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-

26 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-

1 tetrahydrobenzo[c] chromen-1-ol, its isomers,
2 salts, and salts of isomers; Some trade or other
3 names: HU-210, Dexanabinol;

4 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
5 6,6-dimethyl-3-(2-methyloctan-2-yl)-
6 6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol
7 Some trade or other names: HU-211;

8 (37) (2-methyl-1-propyl-1H-indol-
9 3-yl)-1-naphthalenyl-methanone
10 Some trade or other names: JWH-015;

11 (38) 4-methoxynaphthalen-1-yl-
12 (1-pentylindol-3-yl)methanone
13 Some trade or other names: JWH-081;

14 (39) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole
15 Some trade or other names: JWH-122;

16 (40) 2-(2-methylphenyl)-1-(1-pentyl-
17 1H-indol-3-yl)-ethanone
18 Some trade or other names: JWH-251;

19 (41) 1-(2-cyclohexylethyl)-3-
20 (2-methoxyphenylacetyl)indole
21 Some trade or other names: RCS-8, BTW-8 and SR-18;

22 (42) Any compound structurally derived from
23 3-(1-naphthoyl)indole or 1H-indol-3-yl-
24 (1-naphthyl)methane by substitution at the
25 nitrogen atom of the indole ring by alkyl, haloalkyl,
26 alkenyl, cycloalkylmethyl, cycloalkylethyl or

1 2-(4-morpholinyl)ethyl whether or not further
2 substituted in the indole ring to any extent, whether
3 or not substituted in the naphthyl ring to any extent;

4 (43) Any compound structurally derived from
5 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
6 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
7 cycloalkylmethyl, cycloalkylethyl or
8 2-(4-morpholinyl)ethyl, whether or not further
9 substituted in the pyrrole ring to any extent, whether
10 or not substituted in the naphthyl ring to any extent;

11 (44) Any compound structurally derived from
12 1-(1-naphthylmethyl)indene by substitution
13 at the 3-position of the indene ring by alkyl, haloalkyl,
14 alkenyl, cycloalkylmethyl, cycloalkylethyl or
15 2-(4-morpholinyl)ethyl whether or not further
16 substituted in the indene ring to any extent, whether
17 or not substituted in the naphthyl ring to any extent;

18 (45) Any compound structurally derived from
19 3-phenylacetylindole by substitution at the
20 nitrogen atom of the indole ring with alkyl, haloalkyl,
21 alkenyl, cycloalkylmethyl, cycloalkylethyl or
22 2-(4-morpholinyl)ethyl, whether or not further
23 substituted in the indole ring to any extent, whether
24 or not substituted in the phenyl ring to any extent;

25 (46) Any compound structurally derived from
26 2-(3-hydroxycyclohexyl)phenol by substitution

1 at the 5-position of the phenolic ring by alkyl,
2 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl
3 or 2-(4-morpholinyl)ethyl, whether or not substituted
4 in the cyclohexyl ring to any extent;

5 (47) 3,4-Methylenedioxy methcathinone

6 Some trade or other names: Methylone;

7 (48) 3,4-Methylenedioxy pyrovalerone

8 Some trade or other names: MDPV;

9 (49) 4-Methylmethcathinone

10 Some trade or other names: Mephedrone;

11 (50) 4-methoxymethcathinone;

12 (51) 4-Fluoromethcathinone;

13 (52) 3-Fluoromethcathinone;

14 (53) 2,5-Dimethoxy-4-(n)-propylthio-
15 phenethylamine;

16 (54) 5-Methoxy-N,N-diisopropyltryptamine;

17 (55) Pentedrone;

18 (56) 4-iodo-2,5-dimethoxy-N-((2-methoxy
19 phenyl)methyl)-benzeneethanamine

20 (trade or other name: 25I-NBOMe);

21 (57) 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl)

22 methyl]-benzeneethanamine (trade or other name:

23 25C-NBOMe);

24 (58) 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)

25 methyl]-benzeneethanamine (trade or other name:

26 25B-NBOMe).

1 (e) Unless specifically excepted or unless listed in
2 another schedule, any material, compound, mixture, or
3 preparation which contains any quantity of the following
4 substances having a depressant effect on the central nervous
5 system, including its salts, isomers, and salts of isomers
6 whenever the existence of such salts, isomers, and salts of
7 isomers is possible within the specific chemical designation:

8 (1) mecloqualone;

9 (2) methaqualone; and

10 (3) gamma hydroxybutyric acid.

11 (f) Unless specifically excepted or unless listed in
12 another schedule, any material, compound, mixture, or
13 preparation which contains any quantity of the following
14 substances having a stimulant effect on the central nervous
15 system, including its salts, isomers, and salts of isomers:

16 (1) Fenethylline;

17 (2) N-ethylamphetamine;

18 (3) Aminorex (some other names:

19 2-amino-5-phenyl-2-oxazoline; aminoxaphen;

20 4-5-dihydro-5-phenyl-2-oxazolamine) and its

21 salts, optical isomers, and salts of optical isomers;

22 (4) Methcathinone (some other names:

23 2-methylamino-1-phenylpropan-1-one;

24 Ephedrone; 2-(methylamino)-propiofenone;

25 alpha-(methylamino)propiofenone; N-methylcathinone;

26 methcathinone; Monomethylpropion; UR 1431) and its

1 salts, optical isomers, and salts of optical isomers;

2 (5) Cathinone (some trade or other names:

3 2-aminopropiophenone; alpha-aminopropiophenone;

4 2-amino-1-phenyl-propanone; norephedrone);

5 (6) N,N-dimethylamphetamine (also known as:

6 N,N-alpha-trimethyl-benzeneethanamine;

7 N,N-alpha-trimethylphenethylamine);

8 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-

9 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);

10 (8) 3,4-Methylenedioxypropylamphetamine (MDPV).

11 (g) Temporary listing of substances subject to emergency
12 scheduling. Any material, compound, mixture, or preparation
13 that contains any quantity of the following substances:

14 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
15 (benzylfentanyl), its optical isomers, isomers, salts,
16 and salts of isomers;

17 (2) N-[1(2-thienyl)
18 methyl-4-piperidyl]-N-phenylpropanamide (thienylfentanyl),
19 its optical isomers, salts, and salts of isomers.

20 (h) If the Department adopts an emergency rule under
21 Section 10 of the Synthetic Drug Identification Pilot Program
22 Act adding a synthetic drug to the list of Schedule I
23 controlled substances that drug shall be automatically added as
24 a Schedule I controlled substance upon the effective date of
25 the emergency rule. This subsection (h) is inoperative on July
26 30, 2018.

1 (Source: P.A. 97-192, eff. 7-22-11; 97-193, eff. 1-1-12;
2 97-194, eff. 7-22-11; 97-334, eff. 1-1-12; 97-813, eff.
3 7-13-12; 97-872, eff. 7-31-12; 98-987, eff. 1-1-15.)

4 Section 999. Effective date. This Act takes effect upon
5 becoming law.

1

INDEX

2

Statutes amended in order of appearance

3

New Act

4

720 ILCS 570/204

from Ch. 56 1/2, par. 1204